Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - MSN
Yesterday • Google News
Cytokinetics Inc (CYTK)
US$ 30.485-2.63%
Price Chart
Key Statistics
Market Cap
$ 4.09B
P/E Ratio
0.00
Revenue (TTM)
$ 19.22M
Volume
1.26M
52W High
$ 61.38
52W Low
$ 29.31
Dividend Yield
0.00%
Beta
0.59
Technicals
50-Day MA
33.5152
200-Day MA
44.443
52 Week High
61.38
52 Week Low
29.31
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating di.
Employees
498
Headquarters
South San Francisco, CA
CEO
Mr. Robert I. Blum
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg